What is Amolyt Pharma?
Founded in 2014 and headquartered in France, Amolyt Pharma specializes in the development of innovative peptide therapeutics. The company is dedicated to addressing the complex challenges associated with rare endocrine and metabolic disorders, a niche market characterized by significant patient needs and high barriers to entry. By utilizing advanced peptide engineering, Amolyt Pharma aims to deliver transformative treatments that improve patient outcomes. The firm's operational strategy integrates deep scientific expertise with a disciplined approach to clinical development, ensuring that its therapeutic candidates are rigorously evaluated for safety and efficacy before reaching the market.
How much funding has Amolyt Pharma raised?
Amolyt Pharma has raised a total of $316.5M across 6 funding rounds:
Private Equity
$6.6M
Unspecified
$1.9M
Private Equity
$17.1M
Series A
$72.9M
Series B
$80M
Series C
$138M
Private Equity (2014): $6.6M with participation from Octalfa and Bpifrance
Unspecified (2015): $1.9M led by Sham Innovation Santu00e9, Octalfa, and Rhu00f4ne-Alpes Cru00e9ation
Private Equity (2016): $17.1M, investors not publicly disclosed
Series A (2019): $72.9M featuring TAB Consulting, Novo Ventures, Innobio 2, Crédit Agricole Création, Sham Innovation Santé, Life Sciences Partners, Turenne Capital, Pontifax, Orbimed, Partners Innovation Fund, and Kurma Partners
Series B (2021): $80M backed by Kurma Partners, Novo Holdings, ATEM Capital, Sectoral Asset Management, and Andera Partners
Series C (2023): $138M with participation from Kurma Partners, ICG, CTI Life Sciences Fund, Sofinnova Partners, Novo Holdings, Andera Partners, and Tekla Healthcare Opportunities
Key Investors in Amolyt Pharma
Kurma Partners
A key European player in the financing of innovation in healthcare and biotechnology, focusing on projects from pre-seed to growth capital.
Novo Holdings
A Danish private limited liability company wholly owned by the Novo Nordisk Foundation, specializing in long-term life sciences investments.
Andera Partners
A major French private equity firm with a dedicated life sciences team that manages extensive funds for biotech and medtech innovation.
What's next for Amolyt Pharma?
Looking ahead, the infusion of capital will likely be directed toward the expansion of clinical trials and the scaling of manufacturing capabilities for its lead assets. As the company moves deeper into its clinical lifecycle, the focus will shift toward regulatory milestones and potential commercialization strategies. The continued support from a syndicate of specialized life sciences investors provides not only the necessary financial runway but also the strategic guidance required to navigate the complexities of global drug development. Amolyt Pharma remains a key player to watch as it seeks to translate its scientific breakthroughs into tangible clinical benefits for patients suffering from rare metabolic diseases.
See full Amolyt Pharma company page
